Diagnosis and Treatment of Primary Aldosteronism in West China Hospital of Sichuan University from 2009 to 2018

LIU Hong-die, LI Yuan-mei, WANG Wen, LI Qian-rui, CHEN Tao, ZHU Yu-chun, REN Yan, TIAN Hao-ming

Abstract

To summary the clinical diagnosis and treatment of primary aldosteronism (PA) in West China Hospital (WCH) of Sichuan University during 2009-2018.  Methods  This study enrolled the patients diagnosed as PA and admitted in WCH of Sichuan University from January 2009 to December 2018. The information of the patients including epidemiological and clinical data, diagnosis and treatment as well as therapeutic outcomes were collected and analyzed.  Results  A total of 853 patients with 1 248 diagnostic cases were included in the analysis, and the diagnosis cases of PA increased year by year from 2009 to 2018. Most patients (74.33%) were confirmed the diagnosis in the Department of Endocrinology and Metabolism and then admitted to the hospital. PA was more frequent in female than in male, with a ratio of female to male about 1.34∶1. Hypertension was the most common chief complaint, in contrast, the proportion of fatigue and/or numbness as the symptoms of hypokalemia was declining. More and more patients were diagnosed because of imaging examination founding adrenal incidentoma. After 2016, more and more patients were diagnosed by recumbent saline suppression test and captopril challenge test, and the number of adrenal venous sampling to classify PA subtypes was increasing to help choosing different treatment options. The proportion of surgical treatment decreased year by year, and more and more patients adopted medical treatment or transferred to surgery with combined treatment instead of simple operation.  Conclusion  During the past 10 years, remarkable progress was made in the diagnosis and treatment of PA. Hypertension was the most important clinical manifestation of PA, so the screening of PA in hypertensive patients should be strengthened. Adrenal incidentaloma has become prevalent manifestation of PA with an increasing trend, which needs more attention in clinical practice.

 

Keywords: Primary aldosteronism, WCH of Sichuan University, Diagnosis, Treatment

 

Full Text:

PDF


References


SABBADIN C， FALLO F. Hyperal dosteronism: screening and diagnostic tests. High Blood Press Cardiovasc Prev，2016，23(2): 69–72.

FAGUGLI R M， TAGLIONI C. Changes in the perceived epidemiology of primary hyperaldosteronism. Intern J Hypertens， 2011， 2011: 162804[2019-11-01]. http://dx.doi.org/10.4061/2011/162804.

LIM Y Y， SHEN J，FULLER P J， et al. Current pattern of primary aldosteronism diagnosis: delayed and complicated. Aust J Gen Pract， 2018，47(10): 712–718.

YOUNG W F J， CALHOUN D A， LENDERS J W M， et al. Screening for endocrine hypertension: an endocrine society scientific statement. Endocr Rev，2017，38(2): 103–122.

MONTICONE S， D'ASCENZO F， MORETTI C， et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol，2018，6(1): 41–50.

YOUNG W F， Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med，2019，285(2): 126–148. BUFFOLO F， LI Q， MONTICONE S， et al. Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study. Hypertension，2019，74(6): 1532–1540.

BUFFOLO J， BUFFOLO F， DOMENIG O， et al. Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. Hypertension，2020，75(1): 163–172.

WU S， YANG J， HU J， et al. Confirmatory tests for the diagnosis of primary aldosteronism: a systematic review and meta-analysis. Clin Endocrinol，2019，90(5): 641–648.

ROSSI G P， ROSSITTO G， AMAR L， et al. Clinical outcomes of 1 625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension，2019，74(4): 800–808.

FUNDER J W， CAREY R M， MANTERO F， et al. The management of primary aldosteronism: case detection, diagnosis and treatment: an endocrine society clinical practice guideline. J Clin Endocr Metab，2016， 101(5): 1889–1916.

HUNDEMER G L， CURHAN G C， YOZAMP N， et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol，2018，6(1): 51–59.

ROSSI G P， MAIOLINO G， FLEGO A， et al. Adrenalectomy lowers incident atrial fibrillaiton in primary aldosteronism patients at long term. Hypertension，2018，71(4): 585–591.

CHANG Y H， CHUNG S D， WU C H， et al. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism. Surgery，2020，167(2): 367–377.


Refbacks

  • There are currently no refbacks.